These trials utilized different GLP-1 RAs specifically for the treatment of NAFLD/MASLD or NASH, diagnosed either by liver biopsy (in 2 RCTs) or imaging techniques (in 9 RCTs). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.